Navigation Links
ANAVEX completes scale-up manufacturing of ANAVEX 2-73 for Phase I Alzheimer's disease clinical trials
Date:9/21/2009

GENEVA, Sept. 21 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

"With sufficient quantities of ANAVEX 2-73 in hand we are an important step closer to the commencement of Phase I clinical trials, which are scheduled to begin in early 2010," said Dr. Herve de Kergrohen, CEO of ANAVEX. "This lead drug candidate shows potential to alter the course of Alzheimer's disease by using sigma receptors to correct dysfunction in the mitochondria and ultimately protect cells from oxidative stress, which is believed to be an underlying cause of the disease."

ANAVEX will shortly announce the selection of the Contract Research Organization (CRO) in charge of carrying out its Phase I clinical trials. Phase I is the stage at which testing moves to humans. Trials are designed to confirm the drug's safety and determine its tolerability in humans. Pharmacokinetics (the mechanisms of absorption and distribution of the drug, the rate at which a drug begins to act and the duration of its effect, as well as chemical changes of the substance in the body) and pharmacodynamics (physiological effects of drugs on the body, mechanisms of action and relationship between drug concentration and effect) are also studied during Phase I. ANAVEX 2-73 has already demonstrated powerful neuroprotective, anti-amnesic, anti-convulsive and anti-depressive activity in animal models. It also exhibited an excellent safety profile and therapeutic activity at very low doses.

The two kilograms of ANAVEX 2-73 was manufactured by Syntagon AB ("Syntagon") under GMP conditions, the quality assurance system required in the production of medicinal products. Syntagon developed a five-step synthetic procedure that achieved excellent yields in terms of the quantity of the compound that was produced and delivered it to ANAVEX on time.
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
2. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
3. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
4. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
5. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
6. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
7. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
8. SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
9. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
10. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
11. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... und TÜBINGEN, Deutschland, 5. März 2015 /PRNewswire/ ... und das deutsche biopharmazeutische Unternehmen CureVac geben ... Euro (52 Millionen US-Dollar) in CureVac investiert. ... medizinisch angewandten Messenger-RNA (mRNA). Auf Basis dieses ... Behandlung von Krankheiten und zum Schutz vor ...
(Date:3/5/2015)... 2015  BioPhotas, Inc., an FDA registered medical device ... technologies to treat skin, muscle and joint conditions, today ... Fund to provide BioPhotas, flagship product, the Celluma, ... solutions.  Commenting on the alliance, ... the Celluma at the Warrior Hope and Care Center ...
(Date:3/5/2015)... -- Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or the "Company"), ... and acquiring cutting-edge technology, products and services announced today ... at booth # 709 at the National Association ... on March 11-13, 2015 at Caesars Palace in ... The 36 th annual NAPNAP Conference will bring ...
Breaking Medicine Technology:Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3
... April 8, 2011 ImageXpres Corporation (Pink Sheets: ... financial results and annual report that highlighted the key ... 31, 2010. Overall financial results for 2010 demonstrated significant ... and net income of $109,033 for all of 2010, ...
... 8, 2011 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ... of drugs for the treatment of human viral diseases, today ... 18,310,000 shares of its common stock at a public offering ... being sold by Idenix. The offering is expected to close ...
Cached Medicine Technology:ImageXpres Posts OTC Markets 2010 Annual Report 2ImageXpres Posts OTC Markets 2010 Annual Report 3Idenix Pharmaceuticals Prices Public Offering of Common Stock 2
(Date:3/6/2015)... OR (PRWEB) March 06, 2015 Ticket Down ... in Portland, Oregon at the Moda Center. After ... superstar Garth Brooks is showing no signs of letting up ... the country legend and his wife, Trisha Yearwood, to venues ... would be bringing their critically acclaimed tour to the Moda ...
(Date:3/6/2015)... March 06, 2015 Ticket Down is a ... popular ticket exchange has extended their customer appreciation discount code ... Bridge, West Yorkshire England and he began his career in ... the past couple of years Ed Sheeran has become a ... Sheeran is on stage he is having the time of ...
(Date:3/6/2015)... At Natural Products Expo West, Makeena, ... of its powerful, location-aware iOS app that helps ... at any retailer that carries those products, including ... Booth 6054. , Makeena’s proprietary algorithm allows ... Paleo, and vegan, among many other product attributes. ...
(Date:3/6/2015)... Many patients with knee osteoarthritis have continued ... (or someone you know) have chronic pain and problems ... interested in the ACT-OA clinical trial. , Kevin ... is one of fifteen physicians in the U.S. to ... as part of a new, multi-site, double blind, placebo-controlled ...
(Date:3/6/2015)... Raleigh, NC (PRWEB) March 06, 2015 In ... percentage of Polish mesothelioma patients reported that shoulder pain was ... full story on its website. Click here to read ... in Warsaw analyzed the medical records of 49 mesothelioma ... of them reported that it was shoulder pain that first ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:Ed Sheeran Tickets in Indianapolis, Austin, Albany, St. Louis, London, Des Moines, Salt Lake City, Saskatoon, Regina and Denver/Morrison Now On Sale at Ticket Down 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2
... In a study, U.S. researchers have found an increase in the ... the last 50 years//. Girls lose their virginity at the age ... to 15 for which the reasons may be less guilt about ... ,The study done by Jean Twenge, associate professor in psychology at ...
... recent survey it was found that people who were in ... look//. This resulted in an increase in the rates of ... in creating awareness among the procedures used in these surgeries. ... in the number of men and women in their sixties ...
... hundreds of people suffering from gastroenteritis have been admitted in ... reported Monday. ,At least three children have died of ... deaths were reported from southern Punjab, as temperatures shot up ... Dera Ghazi Khan and Bahawalpur. ,More than 150 ...
... over 4,000 people dying in road traffic accidents in the ... senior Delhi Police official. , ,"This city has a ... difficult to control and coordinate the traffic if the standard ... joint commissioner, traffic, said. ,He also said that about ...
... colleges in Delhi went on mass casual leave ... but compounding// the sufferings of patients. ,The ... College (MAMC), University College of Medical Sciences (UCMS) ... express their resentment against the government decision to ...
... 3 years woke up after being administered a sleeping pill, ... hit the research table for thorough clinical testing. , ... tested on 30 patients during the course of this year, ... of coma. After the initial success, the pill has been ...
Cached Medicine News:Health News:Road Traffic Accidents Kill 4,000 people in Delhi 2Health News:Mass Leave By Doctors Leaves Patients Helpless 2
Poly stat Strep A is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid in the diagn...
... The CoaguChek S System offers ... in just one minute requiring only ... enable you to provide more comprehensive ... with each patient. The CoaguChek S ...
The QuickScreen Pro Multi Drug Screening Test is a rapid, self-timing, qualitative immunoassay for,the detection of drugs of abuse in urine....
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: